皮肤直接免疫荧光检测的临床与实验室应用评估
该质量改进研究分析了2012至2020年间2050例连续皮肤直接免疫荧光(DIF)活检,发现仅17.9%阳性,IgG、IgA和C3可识别所有原发性免疫性大疱病,而传统六抗体Panel可能并非必要,提示皮肤科医生对DIF的高价值使用存在知识缺口。
要点
- 仅17.9%的DIF活检阳性,提示反射性六抗体检测可能过度。
- IgG、IgA和C3足以识别所有原发性免疫性大疱病。
- DIF在组织病理确诊的狼疮中阳性率不足一半(23/47,49%)。
核心结论
- 皮肤科医生对DIF的高价值、成本意识使用存在知识缺口,反射性六抗体Panel可能不必要。
研究设计与样本
- 质量改进研究,纳入2012年4月1日至2020年6月12日连续提交的2050例DIF皮肤活检,排除非提交医生本人活检的病例。
主要发现
- 2050例DIF活检中367例(17.9%)阳性。
- IgG、IgA和C3单独即可识别所有原发性免疫性大疱病(类天疱疮、天疱疮、线状IgA病和疱疹样皮炎)。
- IgA、C3和纤维蛋白单独即可识别所有血管炎病例。
- IgG、IgA、IgM和纤维蛋白Panel可识别所有红斑狼疮病例。
- 组织病理确诊的红斑狼疮中DIF阳性率不足一半(23/47,49%)。
临床怎么用
- 根据临床诊断定制DIF抗体Panel可能提高成本效益而不损失敏感性或特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dermatologists submit direct immunofluorescence (DIF) biopsies on a daily basis, using an assay detecting immunoreactant deposition with a panel that has traditionally comprised immunoglobulin (Ig) G, IgA, IgM, C3, and fibrin, with or without albumin antibodies. OBJECTIVES: To evaluate and compare the frequency of immunoreactants in DIF biopsies submitted over an 8-year period and assess use by dermatologists based on clinical impression. DESIGN, SETTING, AND PARTICIPANTS: A quality improvement study was conducted in a community outreach reference laboratory associated with a large academic medical center. Results of 2050 consecutive DIF skin biopsies submitted to the laboratory between April 1, 2012, and June 12, 2020, were analyzed by final pathologic diagnosis and antibody subtype positivity, in comparison with clinical impression. Biopsies in which the submitting physician had not performed the biopsy were excluded. MAIN OUTCOMES AND MEASURES: Histopathologic findings and the results of DIF biopsies using the standard 6-antibody panel were evaluated in correlation with the submitted clinical diagnosis to assess immunoreactivity of the assay. RESULTS: Of 2050 DIF biopsies submitted, 367 (17.9%) were positive; IgG, IgA, and C3 alone identified all primary immunobullous disease cases (pemphigoid, pemphigus, linear IgA, and dermatitis herpetiformis), and IgA, C3, and fibrin antibodies alone identified all vasculitis cases. A panel of IgG, IgA, IgM, and fibrin identified all cases of lupus erythematosus. DIF results were positive in less than half of cases of hematoxylin and eosin biopsy-confirmed lupus erythematosus (23 of 47 [49%]). A total of 247 biopsies were submitted for clinical diagnoses not optimally supported on DIF: lichen planus, porphyria, and connective tissue disease. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that there is a knowledge gap among dermatologists relating to the opportunity for high-value, cost-conscious use of DIF. The practice of reflexive antibody testing using a 6-antibody panel for all DIF biopsies is likely unnecessary. DIF protocols tailored to the clinical diagnosis may enhance cost-effectiveness without loss of test sensitivity or specificity.
引用
- Reimann JDR, Moynihan SP, Horn TD, et al. Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay. JAMA Dermatol. 2021. PMID: 34613346. doi:10.1001/jamadermatol.2021.3892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。